Benalgin - a drug with analgesic, anti-inflammatory, antipyretic and psychoactive effects.
Release form and composition
Benalgin is produced in the form of tablets, the main active ingredients of which are metamizole sodium, thiamine hydrochloride and caffeine.
Whey starch, gelatin, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, and talc are used as excipients in the preparation.
Benalgin is produced in blister packs of 20 pieces per pack.
Indications for use
According to the instructions, Benalgin is used for:
- Weak or moderate pain syndrome (neuralgia, radicular syndrome, headache, toothache, joint pain, myalgia, migraine pain, biliary, renal, intestinal colic, algomenorrhea);
- With an increase in body temperature in infectious-inflammatory and colds (when the diagnosis is precisely established).
Contraindications
According to the instructions, Benalgin does not apply when:
- A high level of patient sensitivity to the components of the drug and other pyrazolone derivatives (tribuzone, butadione);
- Pronounced atherosclerosis;
- Severe renal or hepatic insufficiency;
- Increased intraocular pressure;
- Oppression of bone marrow hematopoiesis;
- Diseases of the hematopoietic system (agranulocytosis, leukopenia, hemolytic anemia);
- Bronchospasm;
- Insomnia;
- Deficiency of glucose-6-phosphate dehydrogenase;
- Uncontrolled arterial hypertension;
- Pregnancy and lactation;
as well as in patients up to 12 years.
Dosing and Administration
Tablets Benalgin intended for oral administration.
Benalgin taken during the first half of the day, 2-3 times after a meal.
Maximum dosage of the drug:
- For adult patients - 2 tablets at a time, but not more than 6 tablets per day for 1-2 days;
- For patients 12-16 years old - 0.5-1 tablet per dose, but not more than 4 tablets per day.
Duration of use Benalgina:
- As an anesthetic - no more than 5 days;
- As antipyretic - no more than 3 days.
The need to increase the daily dosage of the drug and the duration of its use is determined by the doctor.
Side effects
When using Benalgin, certain adverse reactions may predominantly allergic in the form of skin rash, itching, anaphylactic shock, angioedema; possible development of bronchospasm, palpitations, arrhythmia, sleep disorders.
With prolonged use of the drug may occur leukopenia, thrombocytopenia, agranulocytosis.
special instructions
When applying Benalgin should be borne in mind that:
- Overuse of caffeine-containing products can cause symptoms of overdose in the form of nausea, vomiting, pain in the epigastric region, motor and mental stimulation, tachycardia, reduction of diuresis, heart rhythm disturbances, epileptiform seizures. In such situations, an urgent need to seek medical help. For the treatment of drug overdose, gastric lavage is used, followed by the appointment of adsorbents and symptomatic treatment, if necessary;
- It is not recommended to take Benalgin simultaneously with alcoholic beverages;
- In patients with impaired liver and kidney function, the drug is used extremely carefully and under strict medical supervision;
- The drug can affect the pattern of doping tests in athletes;
- In patients with hay fever and atopic asthma, the risk of hypersensitivity reactions is higher than in other patients;
- One should refrain from driving a car and controlling other mechanisms, as well as from performing potentially hazardous activities associated with high concentration of attention and speed of psychomotor reactions;
- The simultaneous use of the drug with NSAIDs and other non-narcotic analgesics leads to mutual enhancement of their toxic effects;
- Oral contraceptives, tricyclic antidepressants and allopurinol lead to impaired metabolism of Benalgin in the liver and increase its toxicity;
- The action of the drug weaken phenylbutazone, barbiturates and other inducers of liver microsomal enzymes;
- The analgesic effect of the drug is enhanced by tranquilizers and sedatives.
Analogs
Analogue of Benalgin is the drug Sedalgin Plus.
Terms and conditions of storage
The drug is stored at a temperature of 15-25º in places not accessible to children, not more than three years.